WESTERN DAY 2017

Adapting to Survive:
Innovation in Reimbursement in Western Canada

Tuesday, September 12, 2017
The Westin Edmonton – Centennial Room
10135 100 Street NW
Edmonton, AB  T5J 0N7
SPEAKERS & PANELISTS

MASTERS OF CEREMONIES:
Fred Horne, Principal of Horne and Associates and Senior Advisor, 3Sixty Public Affairs

KEYNOTE SPEAKER:
Mr. Justin Riemer, ADM for Innovation and Stakeholder Relations, Alberta Health

Louise Binder, Patient Advocacy Leader, Health Policy Consultant

Jennifer Chan, Vice President, Policy and External Affairs, Merck

Michele Evans, Assistant Deputy Minister, Pharmaceutical & Supplementary Benefits Division

Gerry Jeffcott, Senior Associate, 3Sixty Public Affairs

Carole Chambers, Pharmacy Director, Cancer Services, Alberta Health Services

Don Husereau, Health Policy Expert, Health Economist, Member of pERC

Alison Drinkwater, Senior Director, Innomar Consulting

Olaf Koester, Principal, OHWK Business Management Advisory

Heather Logan, Executive Director, CAPCA (TBC)
8:00AM  REGISTRATION & BREAKFAST | NETWORKING

8:45AM  WELCOME & OPENING REMARKS from MASTER OF CEREMONIES:
Fred Horne, Principal of Horne and Associates and Senior Advisor, 3Sixty Public Affairs

9:00AM  KEYNOTE SPEAKER:
Mr. Justin Riemer, ADM for Innovation and Stakeholder Relations, Alberta Health

9:30AM  PANEL SESSION:  *Real World Evidence: Partnering for Success*

**MODERATOR:** Mr. Brad Millson  
**PANELISTS:** Ms. Janey Shin, Ms. Alison Paprica, Dr. Kimberley Simmonds

Experts will provide examples of success stories in data-driven partnerships between industry and government in a variety of clinical areas. Subjects discussed will include the potential benefits for all parties, identifying opportunities for partnership, and recommendations on best practices.

10:15AM  PANEL SESSION:  *The Gathering Storm*

**MODERATOR:** Mr. Ferg Mills  
**PANELISTS:** Dr. Kristian Thorlund, Dr. Matthew Seftel, Dr. Chris McCabe

A discussion of the new wave of therapeutic advances and analytical techniques emerging in cancer care, and how the world of reimbursement will have to change to accommodate their arrival. Panelists will address cellular therapeutics, (e.g. CAR-T technologies), adaptive clinical trials and the need for evolution and innovation in HTA and funding mechanisms.

11:00AM  NETWORKING BREAK

11:30AM  PANEL SESSION:  *Developments in Oncology Reimbursement in Western Canada*

**MODERATOR:** Mr. Gerry Jeffcott  
**PANELISTS:** Ms. Carole Chambers, Ms. Heather Logan, Ms. Jackie Manthorne

Funding oncology treatments is complicated and challenging, and the need for new approaches to evidence generation, financial planning, stakeholder involvement is self-evident. Panelists will reflect on their challenges, experiences and expectations for changes in oncology reimbursement practice, including the Cancer Drug Funding Sustainability Initiative, among other subjects.

12:15PM  PANEL SESSION:  *Patient Input*

**MODERATOR:** Mr. Stephen Filbey  
**PANELISTS:** Ms. Lynda Brown, Ms. Louise Binder, Ms. Jackie Manthorne

Engaging patient support for innovative new therapies has never been more important. Patient input can turn a costly negative recommendation around, but securing that support is no simple undertaking. Panelists will explain their challenges, best practices and techniques that can drive truly meaningful engagement with your patients, to ensure that their voices are heard and the value of innovative treatments is expressed.

1:00PM  LUNCH & NETWORKING BREAK

CAHR reserves the right to cancel or change speakers, program content and date without prior notice. 
We assume no liability for these changes.
2:00PM  **PANEL SESSION:** *Real World Evidence as Real Evidence*

**MODERATOR:** Mr. Olaf Koester  
**PANELISTS:** Ms. Alison Drinkwater, Mr. Don Husereau, Mr. Steve Long  

What should be counted and who should do the counting? How should HTA bodies view RWE, and how can we ensure the results of analyses are fit for purpose? Our expert panel will present their perspectives as policy advisors, expert reviewers, service providers and users of the data.

2:45PM  **PANEL SESSION:** *Reality Check—Funding New Treatments within Constrained Budgets*

**MODERATOR:** Mr. Ferg Mills  
**PANELISTS:** Ms. Michele Evans, Ms. Carole Chambers, Mr. Olaf Koester  

Provincial payers and patient advocates will discuss the harsh realities of securing funding for innovative new treatments, exploring the challenges and solutions they have faced in their various roles.

3:30PM  NETWORKING BREAK

4:00PM  **PANEL SESSION:** *Recognizing and Rewarding Innovation*

**MODERATOR:** Mr. Fred Horne  
**PANELISTS:** Mr. Glenn Monteith, Ms. Louise Binder, Ms. Jennifer Chan  

Despite clear fiscal challenges, industry has recently launched some of the most innovative and genuinely transformative technologies ever seen. In all the discussion about budgets, the value of these new treatments should not be obscured. Our panel will explore industry and patient perspectives on the reimbursement environment, explaining innovative approaches to product listing agreements and the opportunities that new treatments represent for the improvement of public health.

4:45PM  **Q&A/ CONCLUSION**

5:00PM  **CLOSING REMARKS—PROGRAM CONCLUDES**

**SAVE the DATE**  
**Wednesday, November 29, 2017**  
**CAHR’S NATIONAL DAY**  
Meet us in our NATION’S CAPITAL

For more information call Cristina at 416 494 1440 ext. 258 or email cramos@cahr-acrss.ca
Louise Binder, LL.B, LL.D (hon), Patient Advocacy Leader, Health Policy Consultant

Louise is a lawyer and health advocate who has been involved in informing the development of health policy and systemic treatment access practices from a patient perspective for more than 20 years. She started her work in this area in the HIV community in the early 1990s after her own diagnosis and before effective treatments were available for HIV.

She co-founded the Canadian Treatment Action Council (CTAC) in 1996, which successfully ensured access to treatments and quality care for people living with HIV by working with the federal and provincial governments and other relevant stakeholders to enhance drug review and approval systems, pricing policies and access to liver transplants for this community. She wrote a paper on universal drug coverage a decade ago while chair of CTAC.

She had a special interest in women’s issues, chairing the Ontario women's organization Voice of Positive Women for more than a decade, and has been involved in these issues internationally as well. Two years ago, Louise began similar work in the cancer area and is presently a Health Policy Consultant with Save Your Skin Foundation. She has been recognized by many organizations for her work, including receiving an Honorary Doctorate of Laws from her alma mater, Queen’s Law School; the Order of Ontario from the Province of Ontario; and two Queen Elizabeth II medals.

Jennifer Chan, VP, Policy and External Affairs, Merck Canada

Jennifer is responsible for the company's team of government relations and public affairs specialists. Prior to this role, she held the position of Vice President, Policy and Communications at Merck Canada from December 2011. A native of Montreal, Jennifer began her career in academic research before joining Schering-Plough in 1993 as a Clinical Research Associate.

Jennifer is a member of the Board of Directors of the Institute of Health Economics in Alberta, as well as the Quebec Consortium for Drug Discovery and the Quebec Network for Personalized Health Care. She is co-chair of the Canadian Biosimilars Forum and has served as a Merck for Mothers ambassador in Canada since the program was launched in 2011. Jennifer holds a Bachelor of Science degree in physiology and a Master of Science degree in pharmacology and therapeutics, both from McGill University in Montreal.

Carole Chambers, Pharmacy Director, Cancer Services, Alberta Health Services

Carole is the Pharmacy Director of Cancer Services with the Alberta Health Services, with over 30 peer reviewed publications. Carole has received the Distinguished Service Award from the Canadian Association of Pharmacy in Oncology (2005), and an Achievement Award (2006) from the International Society of Oncology Pharmacy Practitioners for longstanding commitment to oncology pharmacy practice through sustained excellence in providing oncology pharmacy services, leadership in innovative oncology pharmacy, related research and ongoing contributions to ISOPP. She served as President for ISOPP between 2008-2010. In 2011, she was awarded Fellowship status with the Canadian Society of Hospital Pharmacists. Recently she has served on an international advisory panel for ISMP in the creation of a medication safety self assessment (MSSA) tool in oncology practice, and has given medication safety presentations in national symposia in Brazil and Canada.

Alison Drinkwater, Senior Director, Innomar Consulting

Alison joined Innomar Strategies in 2016 as Senior Director, Strategic Consulting. She began her career in the fields of communication and marketing more than 15 years ago, then moved to specialize in government relations, health economics and market access at Becton Dickinson and Baxter. Alison was the chair for the HTA (Health Technology Assessment) Committee for the MEDEC Association for two years, working to foster understanding of the differences between medical devices and pharmaceuticals through the payer lens.

Alison has experience in multiple therapeutic areas such as diabetes, oncology, diagnostics and hemophilia, working to examine how the clinical and economic impact of pharmaceuticals and diagnostics could remove market access barriers for patients and clinicians. Alison's market access and health economics experience provides her with a solid foundation to evaluate and understand how the Canadian healthcare system can examine outcomes to ensure universal access and best practices around therapy. Today, she oversees the consulting services offered by Innomar in the areas of strategic consulting, market access, health outcomes evidence generation and market research.
Michele Evans, Assistant Deputy Minister, Pharmaceutical and Supplementary Benefits Division
Pharmaceuticals and Supplementary Health Benefits Division Health

Michele is a pharmacist who has worked for small community pharmacies and large pharmaceutical companies. Michele has been with the Government of Alberta for over ten years in progressive roles; primarily with the Ministry of Health as well as advancing a number of economic development initiatives.

Currently, Michele is accountable for shaping the new divisional priorities as the Assistant Deputy Minister for Pharmaceutical and Supplementary Benefits. The division is responsible for pharmaceutical and supplemental benefits, governance and administration of the Alberta Health Care Insurance Plan and provides leadership in blood services, organ and tissue donation policy and expansion of capacity in acute care services – Lab, DI and Cancer.

Michele is a passionate about the Alberta public service and believes strongly in working collaboratively and making connections. Michele has a Masters in Health Science (Health Administration) degree from the University of Toronto and a Bachelor of Pharmacy degree from the University of Saskatchewan.

Fred Horne, Principal of Horne and Associates and Senior Advisor, 3Sixty Public Affairs

Fred Horne is a health policy consultant and served as Alberta’s Minister of Health from 2011-2014.

A frequent speaker and panelist on health system issues in Canada and abroad, he is Principal of Horne and Associates and Senior Advisor at Ottawa-based 3Sixty Public Affairs. Horne is also Adjunct Professor at the School of Public Health, University of Alberta.

Horne’s career in health policy spans over thirty years and includes extensive experience in policy development and coordination, health system design and transformation, and stakeholder engagement. He has worked extensively with provincial governments, health systems, industry, and research and stakeholder organizations around the world. Current areas of focus include value-based health care initiatives, health technology management, governance and Canadian pharmaceutical policy.

As Minister of Health, Horne was responsible for the province’s $18 billion health budget, the Ministry of Health and Alberta Health Services, the province’s health delivery organization and the fifth largest employer in Canada.

Fred holds an MBA in Executive Management from Royal Roads University and York University’s Certificate in Dispute Resolution. He currently serves as Co-Chair of Mohawk Medbuy Corporation, a national health systems procurement and supply chain management organization, and as a director of the Canadian Physiotherapy Association, the Canadian Frailty Network, and Providence Residential and Community Care Services (BC). He is an Honourary Member of the Canadian Alliance for Health Care Sustainability (Conference Board of Canada), and a member of the C.D. Howe Institute’s Health Policy Council.

Don Husereau, BScPharm, MSc, Health Policy Expert, Health Economist, Member of pERC

Don is a liaison between the Institute and national and international organizations representing government, academia, and industry. In his role, he acts as a key IHE strategist and facilitates the development of activities intended to promote the use of health economics and health technology assessment in health policy and clinical practice. He is a Senior Scientist at the University for Health Sciences, Medical Informatics and Technology in Hall, in Tirol, Austria and an Adjunct Professor of Medicine at the University of Ottawa. He is a former Director and Senior Advisor for the Canadian Agency for Drugs and Technologies in Health (CADTH). He currently leads the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) initiative and is an Editorial Advisor for the journal Value in Health.
Gerry Jeffcott, Senior Associate, 3Sixty Public Affairs
Gerry is a Senior Associate with more than 25 years experience addressing a broad range of pharmaceutical policy issues at the national, federal and provincial levels. He is a recognized expert and commentator on market access and reimbursement issues, having been a mentor, trainer and reporter at different times. For five years, Gerry helped coordinate and support the Industry Oncology Working Group, a coalition of 18 research-based pharmaceutical companies with an interest in cancer policy. He is the co-author of the Council for Continuing Pharmaceutical Education’s Pharmaceutical Market Access in Canada course and he contributes regularly to QuintilesIMS’ strategic information publications, including the Provincial Reimbursement Advisor and PharmaFocus.

Olaf Koester, Principal, OHWK Business Management Advisory; former Director of Manitoba Health Public Drug Plan
Mr. Koester is the Managing Partner, OHWK Business Management Advisory. His professional background includes extensive business management consulting experience to global pharmaceutical manufacturers in the functional areas of Canadian health technology assessment, price negotiations, market access, marketing, pricing, health outcome program development and product utilization strategy development.

In his senior leadership role in the Canadian market access environment, Olaf gained deep insights into: all aspects of the HTA and broader Canadian pharmaceutical system (government, hospital, industry, private sector), health system and government health systems and government policy processes, including provincial formularies, acute care, long-term care, and community/retail business settings government decision-making processes – Common Drug Review (HTA), pan Canadian Oncology Review (HTA), pan Canadian pharmaceutical alliance (national price negotiating organization, listing agreements (Utilization Management Agreements), biologics, biosimilar, speciality drugs, oncology and hospital, and provincial Blood Coordinating Office to facilitate the advancement of transfusion medicine practices and that support the effective and appropriate use of blood and blood products.

As Director, Manitoba Health, Olaf provided expertise, advice, and briefings to the most senior levels of government, including the Premier and the Minister of Health, on all aspects of drug and ancillary benefit program design and management, provincial policies, directives and legislation including utilization management strategies, licensing provisions and practice standards for professionals, product selection, pricing, and reimbursement strategies.

Heather Logan, Executive Director, CAPCA Canadian Association of Provincial Cancer Agencies (TBC)
Bio to follow

Steve Long, President S.C. Long Consulting; former Executive Director, Pharmaceutical Funding and Guidance for Alberta Health
Steve has broad experience in pharmacy services and health care. He started his career in hospital pharmacy and took on increasing responsibility for management and direction of services progressing to Director, Pharmacy Services, Calgary Health Region. From hospital pharmacy Steve moved to take on the challenge of managing drug policy and programs for the government of Alberta. During his five year tenure of responsibility he helped to reshaped pharmacy compensation and reimbursement to better align with expanded scope of practice and streamline review processes to improve access to drugs funded through provincial programs. As National Director, Public Policy for Shoppers Drug Mart, Steve has developed a better understanding of the business of pharmacy and anticipated and interpreted public policy directions of governments to advised senior management on strategies to attain business certainty and evolve the role of pharmacists in the health care system. Steve has created S. C. Long Consulting Ltd. and is available to offer consultation and advice to others seeking to better understand pharmaceutical policy and the Canadian health system.
Jackie Manthorne, President and CEO, Canadian Cancer Survivor Network
Jackie is President and CEO of the Canadian Cancer Survivor Network, a national network of patients, families, survivors, friends, community partners and sponsors. Its mission is to work together by taking action to promote the very best standard of care, support, follow-up and quality of life for patients and survivors. It aims to educate the public and policy makers about cancer and encourage research on ways to alleviate barriers to optimal cancer care in Canada.

Before that, Jackie was CEO for 12 years of a national healthcare charity working in the area of breast cancer. She was a representative on the Global Metastatic Breast Cancer Advocacy Board; a member of the Episodic Disabilities Network; an external reviewer for Health Canada's Population Health Fund and the Canadian Breast Cancer Foundation Ontario Chapter; a judge on the Radio Science Programs Panel of the Canadian Science Writers’ Association; and a member of the Project Advisory Group of the Ovarian Cancer Information Project.

Glenn Monteith, Vice President, Innovation & Health Sustainability
Glenn joined innovative Medicines Canada in November 2015, as the Vice President of Innovation and Health sustainability. Prior to joining Innovative Medicines Canada, Glenn spent the nearly twelve years holding progressively senior positions in the Alberta Ministry of Health, including Executive Director of the Pharmaceutical Policy and Programs Branch, Assistant Deputy Minister of the Health Workforce Division and most recently as Chief Delivery Officer.

Prior to joining Alberta Health and Wellness in 2004, Glenn was Vice President of a strategic communications company based in Victoria, BC. As well, Glenn held several positions with innovative pharmaceutical companies. Glenn was a Senior Consultant and later a Principal with a consulting firm based in eastern Canada that specialized in health care and pharmaceutical initiatives in both the public and private sector.

Glenn also served as Senior Economist at Saskatchewan Health. An economist by training, with more than 25 years working in Canada’s healthcare system, in a variety of roles, both in public and private sector having the unique opportunity with equally committed people wanting the best health care system for those who need it, when they need it.

Glenn is passionate about health care and believes that the health care system need to be positioned as an investment opportunity for all Canadians, rather than a cost-centre, as it is generally managed today.

Brad Millson, Principal, Health Access and Outcomes, QuintilesIMS
Brad is a Principal in QuintilesIMS’s Health Access and Outcomes practice where he is focused on market access strategy and real world evidence solutions. He has 15 years of experience in the Life Sciences industry in Canada and the US, across government and private sectors. Prior to joining QuintilesIMS, Brad led the investment attraction function for Life Sciences at Global Affairs Canada, where he engaged with global pharmaceutical companies to bring new research, development and manufacturing projects to Canada. He also brings experience from the US, with a leading life sciences strategy consulting firm where he led various projects in pipeline development, new product launch and commercial strategy for a range of clients from big pharma and biotech to small and emerging biotechnology and medical device firms.

Dr. Christopher McCabe is the Executive Director and CEO of the Institute of Health Economics (IHE). Dr. McCabe has more than 25 years of experience as an internationally recognized health economist. He was more recently a Professor of Health Economics at the University of Alberta, where he was appointed Capital Health Endowed Research Chair at the University of Alberta, and leads two Genome Canada research groups focused on the evaluation, adoption and implementation of Precision Medicine technologies. He also served on the Canadian Agency for Drugs and Technologies in Health Care (CADTH) Health Economics Working Group, which authored the 4th Edition of the CADTH Guidelines for the Economic Evaluation of Health Technologies earlier this year.

For more information call Cristina at 416 494 1440 ext. 258 or email cramos@cahr-acrss.ca
Prior to his work in Canada, Dr. McCabe was appointed to the Chair in Health Economics at the University of Leeds in 2007, and went on to be the Founding Director of the Academic Unit of Health Economics within the Leeds Institute of Health Science. He has also held Chairs in Health Economics at the Universities of Warwick and Sheffield.

Starting in the early 2000’s, Dr. McCabe worked extensively with the U.K.’s National Institute for Health and Care Excellence (NICE); initially as team leader on the technology appraisal of disease modifying drugs for multiple sclerosis and subsequently as the Founding Director of the NICE Decision Support Unit. He was an expert advisor to the 2008 Edition of the NICE Guide to the Methods of Technology Appraisal, and a member of the writing group for the previous edition in 2003. Dr. McCabe also served as a member of the NICE Medical Technologies Advisory Committee. Prior to his work with NICE, Dr. McCabe worked with local commissioners from U.K.’s National Health Service (NHS), evaluating new technologies to inform funding decisions.

Alison Paprica, PhD PMP, Director, Strategic Partnerships, Institute for Clinical Evaluative Sciences (ICES)

The Institute for Clinical Evaluative Sciences (ICES) is a stand-alone publicly-funded health research institute with data holdings that include all publicly funded health services for the province in Ontario, in many cases going back 20 years or more. As Director, Strategic Partnerships at ICES, Alison leads work to explore and evaluate new initiatives that have the potential to become ICES core business. This includes ICES work with the private sector, which began as a pilot in 2015 and is now a regular service offering, and new initiatives such as the Pan-Canadian Real-world Health Data Network – PRHDN. In addition, she serves as the main coordinating point of contact with key ICES partners including Health Quality Ontario, Cancer Care Ontario and the Ontario SPOR SUPPORT Unit. Alison is also Assistant Professor (Status) at the Institute for Health Policy, Management and Evaluation at the University of Toronto.

Prior to joining ICES, Alison was the Director of the Planning, Research & Analysis Branch at the Ontario Ministry of Health & Long-Term Care, responsible for up to $60-million annual investments in health services and population health research, and extensive knowledge translation and exchange activities to ensure that research findings were understood and used in health system policy development and planning.

From 1994-2001, Alison worked in international pharmaceutical R&D at Eli Lilly, Astra Pharma, and Genpharm Inc. She holds a PhD in organic chemistry from the University of Western Ontario, Project Management Professional (PMP) certification since 2001, and was a fellow in Canadian Foundation for Healthcare Improvement's EXTRA program.

Justin Riemer, Assistant Deputy Minister, Innovation and Stakeholder Relations, Alberta Health at Government of Alberta

As Assistant Deputy Minister (ADM) of Alberta Health’s Innovation and Stakeholder Relations Division, Justin leads his team to facilitate increased innovation adoption in the health care system with the goal of building the strongest health innovation ecosystem in Canada. This goal will be achieved by actively engaging with health system providers, leading and emerging health industry firms, post-secondary institutions and others to drive collaboration across the health care system. The objective is to accelerate the adoption and diffusion of new innovative health technologies and processes that will improve patient outcomes and add value to the system.

The team develops proactive approaches to strengthen Alberta Health’s external engagement capacity, providing guidance to support the engagements of other Alberta Health divisions, and developing new stakeholder partnerships to promote improved health care outcomes in the province. Since 1996 the Government of Alberta has been Justin’s employer of choice. He has had the opportunity to provide leadership and drive results in a variety of areas including research and innovation, economic development, competitiveness, international marketing, strategic planning and policy development. He holds a Master’s Degree in International Affairs from Carleton University.
Dr. Matthew Seftel, MBChB MPH FRCP FRCP, Hematology and Oncology at CancerCare Manitoba

Coming from a distinguished family of physicians, Matthew obtained his medical degree from the University of Cape Town South Africa and is a Fellow of the Royal Colleges of Physicians of London (UK) and Canada. In addition he has a Masters degree in Public Health from Johns Hopkins University.

Dr. Seftel is presently the Head of the Department of Medical Oncology and Hematology at CancerCare Manitoba and the Section of Hematology/Oncology, Department of Internal Medicine, at the University of Manitoba, where he holds an Associate Professorship. He has supervised numerous research projects and post-graduate theses and received a number of teaching and service awards.

He is no stranger to peer review committees for CIHR other granting agencies and trial groups (NCIC). He is sought after by many journal review boards. He has over 80 peer reviewed publications and 4 book chapters as well as numerous peer-reviewed abstracts.

His research interests include leukemia epidemiology, as well as clinical trials in leukemia and lymphoma, including Blood and Marrow Transplantation. He is an investigator with the Canadian Cancer Trials Group (CCTG) and the Centre for International Blood and Marrow Transplant Research (CIBMTR).

Outside of work, Matt enjoys long-distance running, despite the prairie weather; sometimes this includes running after his 2 energetic young boys, Gus and Leo.

Janey Shin, Director, Real World Evidence, Janssen Pharmaceutical

Janey is responsible for developing the Janssen RWE strategy for Canada and for driving high-priority evidence research projects through partnerships with healthcare, government, academic, research, and data provider organizations.

Prior to Janssen, Janey was the Director of Medical Affairs at Johnson & Johnson Medical Companies (JJMC) Canada, where she lead the development and execution of Medical Education, Clinical Affairs, Health Economics and Market Access, and Medical Information strategies across all franchise portfolio of medical device products.

Prior to Johnson & Johnson, she was the Director of Analytics and Surveillance at the Canadian Partnership Against Cancer and was responsible for driving key oncology pan-Canadian initiatives, including enhancing surveillance systems, developing health economic system decision-making tools, and building analytic capacity through engagement and partnerships with federal, provincial and territorial stakeholders.

Over the last two decades, Janey has had progressive roles in statistics, clinical operations, sales and marketing operations, and Lean Six Sigma. She holds an MBA from the Rotman School of Management.

Dr. Kimberley Simmonds, PhD, Director, Health Evidence & Policy, Alberta Ministry of Health

Dr. Simmonds has a PhD in hospital epidemiology with expertise in research methodology, infectious disease epidemiology and surveillance. Her current role has responsibilities including: leading provincial health technology assessments, collaborating with key stakeholders at the local, provincial, and national levels to ensure evidence is available to guide policy and to progress the liberation of health data in Alberta. Kim is an adjunct professor at the University of Calgary and University of Alberta.

Kristian Thorlund, Professor of Biostatistics, McMaster University

Kristian is an adjunct professor of biostatistics at McMaster University and senior scientific advisor to the Bill & Melinda Gates Foundation. He ranks among the top 1% highly cited researchers internationally in the past decade and has published well over 100 peer reviewed research papers in high impact medical and statistics journals. His research focuses on Bayesian statistical methods, innovative clinical trials designs and network meta-analysis. Kristian previously served as the co-founding and managing partner of Redwood Outcomes (acquired by Precision Medicine Group, November 2015), the world-leading provider of network meta-analysis. Prior to co-founding Redwood Outcomes, Kristian also held an appointment as visiting associate professor at Stanford University.

CAHR reserves the right to cancel or change speakers, program content and date without prior notice. We assume no liability for these changes.
Name__________________________________________________________________________________
Company________________________________________________________________________________
Address________________________________________________________________________________
City______________________ Province____________________ Postal Code____________________
Email__________________________________________________________________________________
Cell No____________________________     Office No________________________    Ext.______________
Special and/or Dietary Needs________________________________________________________________

**COST:** Includes program materials, breakfast, lunch two breaks

☐ CAHR Member: $850  ☐ Non-Member: $995.00  ☐ Student: $75.00

**PAYMENT METHOD:** ☐ Cheque CDN$ payable to CAHR   ☐ VISA   ☐ MasterCard   ☐ Amex

**Total $_______________________** 5% HST is applicable, #85788 9901 RT0001.

Name of Cardholder:______________________________________________________________________

Credit Card Number:_____________________________ Expiry Date:_______ CVV #:_______

Credit Card Billing Address:________________________________________________________________

City:________________________ Province:__________ Postal Code:________________

**HOTEL INFORMATION:**
The Westin Edmonton – Centennial Room
10135 100 Street NW
Edmonton, AB T5J 0N7
1-800-937-8461 reference CAHR-Western Day

**HOW TO REGISTER:** You can register online at www.cahr-acrss.ca or mail your completed registration form with your payment to: CAHR, 301-250 Consumers Road, Toronto, ON M2J 4V6. Fax to 416-495-8723. Please retain a copy of your registration form for your records.

An **Electronic copy of your receipt will be issued by email once payment has been received and processed.**

**CANCELLATION POLICY:**
A full refund will be issued for cancellations received in writing before Sept 5. No refunds after Sept 5.
THANK YOU TO ALL OF OUR EVENT PARTNERS!